ANT-GROUP
16.6.2022 05:03:07 CEST | Business Wire | Press release
Ant Group today announced the launch of Alipay+ Unified Payment. This major product upgrade provides a unified, scalable technical solution to help online and brick-and-mortar merchants collect money through all digital payment methods supported by Alipay+ in a more convenient and effective way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006164/en/
Alipay+ offers a suite of innovative cross-border digital payments and marketing solutions, enabling merchants, especially small and medium-sized businesses, to better serve consumers worldwide. With this upgrade, Alipay+ Unified Payment further helps merchants directly reach over one billion consumers by making it easier for them to pay. Going forward, digital payment users in different countries can make cross-border payment with their local currencies wherever they see an Alipay+ sign, either online or offline, if the mobile payment methods they use adopt Alipay+ solutions.
After online merchants integrate Alipay+ Unified Payment, consumers will see an Alipay+ option when they make payments in their cashier pages. Cashiers will present users who choose to pay through Alipay+ recommended digital payment methods it supports based on their countries and payment preferences. Users can then proceed with paying using their preferred digital payment method. Brick-and-mortar merchants integrate Alipay+ Unified Payment by adopting a unified QR code scheme and scan-to-pay services, which can accept all digital payment methods enabled by Alipay+.
Alipay+ Unified Payment brings merchants highly efficient and cost-optimized digitalized cashier experiences. After one-time integration, merchants can accept all available digital payment methods, including existing methods and ones to be introduced by Alipay+ later on. Moreover, with innovative and digital-native technologies, Alipay+ can be integrated into merchants’ own systems with a simple technical adaption. Alipay+ Unified Payment also provides marketing services as part of its cashier solutions to help merchants expand the reach of targeted potential users.
Alipay+ Unified Payment began its pilot phase in May 2022. Merchants, including Buygogo, an e-commerce platform and Smile.one, one of the leading top-up services for online games and entertainment, have participated in the pilot program.
“We’re excited to launch Alipay+ Unified Payment, a one-stop solution integrating a wide range of digital payment methods. This upgrade helps merchants handle digital payments more conveniently and seamlessly, and greatly improves their operating efficiency,” said Cheng Guoming, General Manager of Alipay+ Global Partnership, Ant Group. “We are dedicated to leveraging our innovative products and technologies to better serve merchants around the world and facilitating even more cross-border business activities as the global economy recovers from the pandemic.”
About Alipay+
Alipay+ provides global cross-border digital payments and marketing solutions that enable global e-wallets and merchant partners, especially small and medium-sized businesses, to better serve their users and customers.
Alipay+ is introduced by Ant Group, the owner and operator of Alipay. As one of the world’s leading digital payment platforms, Alipay serves hundreds of millions of users by connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom